Covered recipient · General Payments record
SIRINAN TAZEN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$1,980.73
- Reported across 34 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $336.81 | 16 |
| Education | $13.40 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| EISAI INC. | $85.27 | 4 |
| PFIZER INC. | $65.83 | 3 |
| ABBVIE INC. | $41.62 | 2 |
| Sumitomo Pharma America, Inc. | $28.83 | 1 |
| Neurelis, Inc. | $28.48 | 2 |
| Neurocrine BioSciences, Inc. | $28.39 | 1 |
| Amneal Pharmaceuticals LLC | $20.98 | 1 |
| Biogen, Inc. | $18.21 | 1 |
| Teva Pharmaceuticals USA, Inc. | $17.20 | 1 |
| Lilly USA, LLC | $15.40 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.80 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106207681 | CMS |
| ABBVIE INC. | $22.82 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106207683 | CMS |
| Amneal Pharmaceuticals LLC | $20.98 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139203586 | CMS |
| Biogen, Inc. | $18.21 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104821332 | CMS |
| Eisai Inc. | $18.88 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110781746 | CMS |
| Eisai Inc. | $24.20 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110781748 | CMS |
| Eisai Inc. | $20.42 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110781750 | CMS |
| Eisai Inc. | $21.77 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110781752 | CMS |
| Lilly USA, LLC | $15.40 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135427310 | CMS |
| Neurelis, Inc. | $13.40 | 08/29/2024 | Education | Undisputed | 01/23/2026 | 1145656950 | CMS |
| Neurelis, Inc. | $15.08 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145656952 | CMS |
| Neurocrine Biosciences, Inc. | $28.39 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150829696 | CMS |
| PFIZER INC. | $23.87 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131225969 | CMS |
| PFIZER INC. | $21.74 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131859919 | CMS |
| PFIZER INC. | $20.22 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131968481 | CMS |
| Sumitomo Pharma America, Inc. | $28.83 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148927098 | CMS |
| Teva Pharmaceuticals USA, Inc. | $17.20 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151570031 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2022, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.